Gi­ant Roche wades in­to the pre­clin­i­cal NL­RP3 pool, bag­ging Je­cure for their an­ti-in­flam­ma­to­ry team at Genen­tech

You can now count the bio­phar­ma gi­ant Roche among the grow­ing num­ber of play­ers fas­ci­nat­ed by the po­ten­tial of NL­RP3 in­hi­bi­tion.

Their big Cal­i­for­nia sub­sidiary …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.